Health Care/Hospital

Gilead Sciences Announces Launch of Asia Pacific Rainbow Grant 2021

- Grant Program Invites Applications from HIV-Focused Community-Based Organizations in the Asia Pacific Region to Fund Innovation Projects - - To Date, Grant Has Awarded Nearly US $3 Million to Organizations Across Asia Pacific - HONG KONG, March 29, 2021 /PRNewswire/ -- Gilead Sciences, Inc. to...

2021-03-29 11:00 2489

Navigating China's Medical Technology, Regulations, Quality, and Future; Hundreds of Experts Gathered at On-site Conferences of Medtec China

SHANGHAI, March 29, 2021 /PRNewswire/ -- Medtec China 2021 will be held in Halls 2&4 of the Shanghai World Expo Exhibition Hall on September 1–3, and the "Innovation Technology Forum and Regulation Summit" will be held at the same time. This summit caters to the development trend and focus of Ch...

2021-03-29 09:30 3683

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint

SHANGHAI, March 29, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail t...

2021-03-29 08:27 4953

Making Most out of Launched Products Fueling Diversified Innovation through Integrated Platform

SHANGHAI, March 28, 2021 /PRNewswire/ -- Henlius (2696.HK) announced the financial results for the year ended31 December 2020. 2020 marked a meaningful year for Henlius as the Company gathered the pace in commercialization and continued the momentum for innovation. The Company delivered a total r...

2021-03-28 11:16 3680

Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS

TAIPEIMarch 27, 2021 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), today announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with associated...

2021-03-28 11:04 3018

China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results

HAIKOU CITY, China, March 26, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the ...

2021-03-27 05:00 9944

FARE Launches Global Research Competition to Develop a Safe & Compassionate Diagnostic Test for Patients with Food Allergies

- $3 Million in Prize Money Inspires the World's Leading Food Allergy Researchers to Put an End to the Oral Food Challenge - Aimmune Therapeutics - Nestlé Health Science Partnership, Financial Support & Global Reach Anchor FAITH Challenge MCLEAN, Va., March 27, 2021 /PRNewswire/ -- FARE, the wor...

2021-03-27 04:25 3423

Genscript Biotech Reports Full Year 2020 Financial Results

Highlights: * Revenue of the Group for the year ended December 31, 2020 was approximately US$390.8 million, representing an increase of 42.9% as compared with approximatelyUS$273.4 million for the year ended December 31, 2019 * Gross profit of the Group for the year ended December 31, 2...

2021-03-27 02:16 7345

Modern Chinese Medicine Announces Year 2020 Annual Results

Solid growth with focus to broaden the distribution network and raise R&D efforts PERFORMANCE HIGHLIGHTS * The Group posted a consolidated revenue of approximately RMB308.7 million for the year ended31 December 2020, representing an increase of approximately 41.1%. * For the year ended 31 D...

2021-03-26 22:08 12495

Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years

BAGSVÆRD, Denmark, March 26, 2021 /PRNewswire/ -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years...

2021-03-26 21:31 4035

Kintor Pharmaceutical Limited Announces 2020 Business Progress and Annual Results

SUZHOU, China, March 26, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing small molecule and biological therapeutics, recently announced its business highlights and financial result...

2021-03-26 20:54 6921

InnoCare Releases 2020 Annual Results and Business Highlights

BEIJING, March 26, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2020 annual results which ended onDec. 31, 2020. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "During 2020...

2021-03-26 19:39 6200

Artificial Joint Surgical Robot, CUVIS-joint developed by CUREXO Receives EEA CE Marking

* Expands partnership with European implant and medical enterprises * Pursues US FDA approval SEOUL, South Korea, March 26, 2021 /PRNewswire/ -- On the 25th, medical robot company CUREXO, Inc. (KOSDAQ: 060280) announced that the in-house developed artificial joint surgical robot CUVIS-joint re...

2021-03-26 17:00 3690

Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)

Initiating Phase 1b randomized clinical trial with initial results expected in late 2021 Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants CINCINNATI, March 26, 2021 /PRNewswire/ --...

2021-03-26 16:00 3511

China Life Singapore Provides Complimentary "COVID-19 Vaccine Protection" Coverage to Customers

SINGAPORE, March 26, 2021 /PRNewswire/ -- In view of the current situation of COVID-19 pandemic development, China Life Singapore is committed to taking care of its customers[1] by offering a "COVID-19 Vaccine Protection" coverage. The promotion period is valid from 23 March 2021 to 30 June 2021....

2021-03-26 14:06 2746

Ascentage Pharma Announces Publication of Preclinical Data in Nature Immunology Showing Enhanced T-Cell-Mediated Antitumor Immunity Induced by Its MDM2-p53 Inhibitor APG-115

SUZHOU, China and ROCKVILLE, Md., March 26, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the peer-reviewed publicati...

2021-03-26 08:38 3172

Antengene Announces Financial Results for Full Year 2020

SHANGHAI and HONG KONG, March 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" or "the company", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in h...

2021-03-26 08:00 4382

Chime Biologics Announced the Completion of US$190 Million Series A+ Financing to Accelerate Capacity Expansion

WUHAN, China, March 26, 2021 /PRNewswire/ -- Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment ofUS$190 million investment from institutional investors, and over $100 million investment has already been closed today. This round of fin...

2021-03-26 08:00 5777

Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round

CINCINNATI, March 26, 2021 /PRNewswire/ -- Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at$4 million. Investments ...

2021-03-26 05:19 3563

Antengene Appoints Kevin Lynch as Chief Medical Officer

SHANGHAI, China and MELBOURNE, Australia, March 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in ...

2021-03-25 23:26 4458
1 ... 818819820821822823824 ... 858